Chemomab Therapeutics Ltd. (CMMB) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.18 (+1.72% 1D, market cap $9.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CMMB ranks #778 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMMB carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BFRG (Bullfrog AI Holdings Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $9.0M) and PTN (Palatin Technologies Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M). Among the 5-stock peer group, CMMB leads on earnings multiple (N/A) while CMMB leads on capital efficiency (-35.0% ROIC).
Per CMMB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534248), Chemomab Therapeutics Ltd. generated $313.6M in revenue (+8.7% YoY), -$9.0M in net income, and -$11.1M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 38.7 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While CMMB currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.86) and Max Pain ($1.24) forces dealer call-delta covering toward $3.22.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Chemomab Therapeutics Ltd. (CMMB) advanced +1.72% to $1.18, trading at 12% of its 52-week range ($0.92 – $3.07). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics (Nasdaq: CMMB) (“Chemomab
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CMMB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CMMB. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Chemomab Therapeutics Ltd. (CMMB) ranks #778 by composite RQD confidence (31/100, grade E) and #897 by equity capitalization ($9.3M). Within this direct 5-issuer industry benchmark cohort, CMMB leads on earnings valuation at N/A trailing P/E, while CMMB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CMMB at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CMMB
ACTIVE
Chemomab Therapeutics Ltd. | E | 31/100 | — | — | -35.0% | +1.72% | $9.3M | Benchmark Subject |
| BFRG Bullfrog AI Holdings Inc. | E | 32/100 | — | 18.8% | -35.0% | +1.78% | $9.0M | /bfrg-vs-cmmb → |
| PTN Palatin Technologies Inc. | D- | 35/100 | — | — | -35.0% | -0.20% | $8.9M | /ptn-vs-cmmb → |
| LTRN Lantern Pharma Inc. | E | 31/100 | — | — | -35.0% | -3.15% | $9.9M | /ltrn-vs-cmmb → |
| BLRX BioLineRx Ltd. | D | 46/100 | — | — | — | -1.51% | $9.9M | /blrx-vs-cmmb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Chemomab Therapeutics Ltd. (CMMB) reported GAAP revenue of $313.6M (+8.7% vs. FY2024 revenue of $288.4M , and +187.7% cumulative change since FY2023) , GAAP net income of -$9.0M, operating cash flow of -$11.1M, and free cash flow of -$11.1M (+27.6% YoY). On the balance sheet, CMMB closed FY2025 with $13.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $313.6M | -$9.0M | -$11.1M | -$11.1M | $13.8M | — |
| FY2024 (FY) | 2024-12-31 | $288.4M | -$13.9M | -$15.4M | -$15.4M | $17.0M | — |
| FY2023 (FY) | 2023-12-31 | $109.0M | -$24.2M | -$23.6M | -$23.6M | — | — |
As of 2026-11-03, Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.18 (+1.72% 1D, market cap $9.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CMMB ranks #778 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMMB carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BFRG (Bullfrog AI Holdings Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $9.0M) and PTN (Palatin Technologies Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M). Among the 5-stock peer group, CMMB leads on earnings multiple (N/A) while CMMB leads on capital efficiency (-35.0% ROIC).
Per CMMB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534248), Chemomab Therapeutics Ltd. generated $313.6M in revenue (+8.7% YoY), -$9.0M in net income, and -$11.1M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CMMB last traded at $1.18 (+1.72% on volume of 76,443 shares), positioning the stock -36.56% below its 50-day simple moving average ($1.86) and -32.57% below its 200-day simple moving average ($1.75). Across its 52-week range of $0.92 to $3.07, CMMB sits at the 12.1% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.03 to $1.33).
Chemomab Therapeutics Ltd. (CMMB) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.18 (+1.72% 1D, market capitalization $9.3M).
Chemomab Therapeutics Ltd. Is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..0B in that section. — for product lines, customers, or revenue model; the financials report — revenue across the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Chemomab Therapeutics Ltd. (CMMB) reported $313.6M in annual revenue (up from $288.4M in FY2024, +8.7% YoY) and -$9.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($109.0M revenue, -$24.2M net income) through FY2025, CMMB scaled operating cash flow to -$11.1M and free cash flow to -$11.1M, backed by $13.8M in total assets against $0 in total debt.
Upstream and downstream dependencies are therefore — Sector correlations beyond the stated Health Care sector and beta of 1.0 are — The principal second-order variable visible in the data is the pending merger: if the vote and financing proceed, the capital structure and share count could change materially relative to the $8.8M market capitalization shown here; this is an inference about implications rather than a sourced figure.
Real-time company headlines, analyst actions, and sector developments for Chemomab Therapeutics Ltd. (CMMB) • Click "Debate This Headline" to argue it in the Roar Pit below
Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.
Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics (Nasdaq: CMMB) (“Chemomab
The street is overcomplicating Chemomab Therapeutics Ltd. (CMMB). Forensic balance-sheet pillar scores 10/20 with reported cash of $7.6M and Debt/Equity of 0.5.. With an RQD score of 31/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.25.
Both sides have a point here — CMMB's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
ROIC of -35%, zero revenue, and FCF yield of 0% leave no cash-flow support for the $1.09 price.. Look at the math on CMMB: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.02 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).